Hyperion DeFi, Inc.
NCM: HYPDLive Quote
📈 ZcoreAI Score
Our AI model analyzes Hyperion DeFi, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get HYPD Z-Score →About Hyperion DeFi, Inc.
Healthcare
Biotechnology
Hyperion DeFi, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi; and agreement with Formosa Pharmaceuticals. Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as Eyenovia, Inc. and changed its name to Hyperion DeFi, Inc. in July 2025. Hyperion DeFi, Inc. was founded in 2014 and is based in New York, New York.
📊 Fundamental Analysis
Hyperion DeFi, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported 1666.4% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -324.1%, which indicates that capital utilization is currently under pressure.
At a current price of $3.63, HYPD currently trades near the bottom of its 52-week range (16%), indicating potential value or weakness (Range: $0.96 - $17.18).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$41.35M
Trailing P/E
--
Forward P/E
--
Beta (5Y)
2.63
52W High
$17.18
52W Low
$0.96
Avg Volume
388K
Day High
Day Low